stockrow
Saturday 7 November 2026
Export FTH’s income statement to Excel — free account
Faeth Therapeutics, Inc.
- EPS
- +78.2%
- Free cash flow
- −262.7%
Quarter to September 2026, against a year earlier
21.86
1.94
+9.74%
Follow FTH
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.06 | 7.70 | 11.92 | 11.98 | 30.38 | 4.16 | 0.02 | 0.48 | — |
Net Debt/EBITDA |
0.96 | 1.32 | 1.82 | 2.16 | 3.97 | 0.90 | (1.44) | (0.32) | — |
Debt/Assets |
0.00% | 0.22% | 1.03% | 1.33% | 1.09% | 3.05% | 1,319.23% | 256.54% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.02 | 0.01 | (0.01) | (0.23) | (0.80) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.97 | 0.82 | 0.94 | 0.80 | 0.82 | 0.88 | 0.42 | 0.61 | — |
Capex/Depreciation |
1.68 | (0.11) | (0.01) | (0.23) | (2.49) | (0.67) | (0.04) | 0.00 | — |
Interest Coverage |
(696.50) | (362.38) | (257.39) | (229.17) | (55.94) | (11.52) | (5.51) | (77.92) | — |
| (74.01%) | (58.40%) | (40.52%) | (38.88%) | (81.70%) | 32.30% | 33.64% | 27.58% | — | |
| (61.78%) | (50.37%) | (35.38%) | (35.78%) | (42.13%) | (178.44%) | (1,339.68%) | (1,820.86%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (4,138.91%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(121.61%) | (81.73%) | (54.33%) | (47.84%) | (24.81%) | (122.36%) | 98.09% | 1,336.75% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(16.03) | (19.76) | (22.92) | (25.62) | (23.07) | (234.63) | (469.51) | (0.35) | — |
Cash per Share |
16.80 | 32.91 | 47.05 | 69.77 | 106.54 | 205.91 | 13.67 | 0.02 | — |
Shareholders Equity per Share |
14.74 | 30.56 | 46.43 | 67.36 | 105.74 | (700.29) | (3,738.14) | (0.20) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
14.74 | 30.56 | 46.43 | 67.36 | 105.74 | (700.29) | (3,738.14) | (0.20) | — |
Free Cash Flow |
(20.22) | (24.82) | (32.04) | (39.33) | (31.97) | (18.91) | (8.62) | (10.31) | — |
Working Capital |
17.26 | 36.48 | 61.61 | 99.52 | 143.65 | 15.25 | (21.21) | (1.38) | — |
Capital Expenditures |
0.23 | (0.15) | (0.01) | (0.31) | (1.71) | (1.21) | (0.05) | (0.03) | — |
Net Current Asset Value |
17.20 | 34.95 | 57.77 | 93.62 | 141.83 | (57.79) | (69.38) | (6.50) | — |
| Other line items | |||||||||
Quick Ratio |
4.98 | 7.59 | 11.65 | 11.82 | 30.19 | 3.44 | 0.01 | 0.25 | — |
Depreciation/Fixed assets |
1.70 | 3.17 | 1.16 | 0.66 | 0.15 | 1.41 | 5.47 | 0.36 | — |
Cash ROIC |
(50.83%) | (31.09%) | (24.38%) | (18.54%) | (10.81%) | 48.25% | 16.47% | 1,924.07% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9,191.36 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(16.22) | (19.64) | (22.91) | (25.42) | (21.84) | (219.66) | (466.63) | (0.35) | — |
Capex per Share |
0.19 | (0.12) | (0.01) | (0.20) | (1.23) | (14.96) | (2.89) | 0.00 | — |
Average Payables |
1.36 | 1.47 | 3.08 | 3.46 | 3.17 | 3.71 | 2.33 | 2.28 | — |
Average Assets |
34.13 | 59.87 | 96.37 | 135.80 | 87.33 | 11.32 | 1.53 | 0.93 | — |
Average Common Equity |
28.49 | 51.64 | 84.15 | 124.96 | 45.04 | (62.55) | (61.07) | (61.07) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 5 Nov 2026